We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Reply: Costs of managing adverse events in the treatment of first-line metastatic renal cell carcinoma: bevacizumab in combination with interferon-α2a compared with sunitinib.
- Authors
Mickisch, G. H. J.; Escudier, B.; Walzer, S.; Nuijten, M.
- Abstract
A response by G. H. J. Mickisch and colleagues to a letter to the editor on their article "Costs of managing adverse events in the treatment of first-line metastatic renal cell carcinoma: bevacizumab in combination with interferon-α2a compared with sunitinib" in the 2010 issue is presented.
- Subjects
LETTERS to the editor; RENAL cell carcinoma; CANCER treatment
- Publication
British Journal of Cancer, 2010, Vol 103, Issue 8, p1309
- ISSN
0007-0920
- Publication type
Letter
- DOI
10.1038/sj.bjc.6605887